How Can We Help You?
There may be options to help you afford your Genentech medicine, no
matter what type of health insurance you have.
If you need help with the co-pay for your Genentech medicine, LUCENTIS Access Solutions can refer you to an independent co-pay assistance foundation.
An independent co-pay assistance foundation is a charitable
organization that gives financial assistance for medicines.
Call LUCENTIS Access Solutions at (866) 724-9394 for a referral.
If you would like to contact a foundation directly, you can use the information below:
Diabetic Macular Edema
Macular Edema Following Retinal Vein Occlusion
Wet Age-Related Macular Degeneration
Diabetic Retinopathy (DR)
Myopic Choroidal Neovascularization
Independent co-pay assistance foundations have their own rules for
eligibility. We cannot guarantee a foundation will help you. We only
can refer you to a foundation that supports your disease state. This
information is provided as a resource for you. We do not endorse or
show financial preference for any particular foundation. The
foundations in this list are not the only ones that might be able to
The Genentech® Access to Care Foundation is now the Genentech Patient Foundation.
We are still focused on giving free medicines to patients in need, but we've made some changes to provide better support to more patients, more quickly.
The Genentech Patient Foundation provides free medicines to
- Who don't have insurance
- Whose treatment is not covered by insurance
are struggling with high out-of-pocket costs
To learn more and to apply for help, visit GenentechPatientFoundation.com.
If you have health insurance coverage for your medicine, you must have already tried other types of patient assistance to qualify for free Genentech medicine from the Genentech Patient Foundation. This includes the LUCENTIS Co-pay Program and support from independent co-pay assistance foundations. You must also meet financial criteria. If you do not have insurance or your insurance does not cover your medicine, you must meet different financial criteria.
LUCENTIS Access Solutions can refer you to the LUCENTIS Co-pay Program. It can help you with the out-of-pocket costs for your Genentech medicine, if you’re eligible.
The LUCENTIS Co-pay Program helps patients with commercial health
insurance. This might be a plan you get through your employer or one
you purchased through a Health Insurance Marketplace like
HealthCare.gov. To qualify, you must also meet other criteria.
In order to be eligible for the LUCENTIS Co-pay Program, the
patient must have commercial insurance, must not have Medicare,
Medicaid or other government insurance, and must meet other
eligibility criteria. They also must agree to the rules set forth in
the terms and conditions for the program. Please visit LUCENTISCopayProgram.com for the full list of
terms and conditions.
How to Work With LUCENTIS Access Solutions
PAN=Patient Authorization and Notice of Request
for Transmission of Health Information to Genentech Access Solutions
and Genentech® Access to Care Foundation.
SMN=Statement of Medical Necessity.
Important Safety Information & Indication
What it Treats
LUCENTIS® (ranibizumab injection) is a prescription medicine for the treatment of patients with:
- wet age-related macular degeneration (wAMD),
- macular edema following retinal vein occlusion (RVO)
- diabetic macular edema (DME)
- diabetic retinopathy (DR) with DME
- myopic choroidal neovascularization (mCNV)
Important Safety Information
You should not use LUCENTIS if you have an infection in or around the eye or are allergic to LUCENTIS or any of its ingredients. LUCENTIS is a prescription medication given by injection into the eye, and it has side effects. Some LUCENTIS patients have had detached retinas and serious eye infections. If your eye becomes red, sensitive to light, or painful, or if you have a change in vision, call or visit your eye doctor immediately. Some LUCENTIS patients have had increased eye pressure before and within 1 hour of an injection. Uncommonly, LUCENTIS patients have had serious, sometimes fatal, problems related to blood clots, such as heart attacks or strokes. Fatal events were seen more often in patients with DME and DR with LUCENTIS compared with patients who did not receive Lucentis. Although there were only few fatal events, which included causes of death typical of patients with advanced diabetic complications, these events may be caused by Lucentis.
Some LUCENTIS patients have serious side effects related to the injection. These include serious infections inside the eye, detached retinas, and cataracts. The most common eye-related side effects are increased redness in the white of the eye, eye pain, small specks in vision, and increased eye pressure. The most common non–eye-related side effects are nose and throat infections, anemia, nausea and cough. Ask your doctor if you have questions or want more information.
You may report side effects to the FDA at (800) FDA-1088 or www.fda.gov/medwatch. You may also report side effects to Genentech at (888) 835-2555.
For additional safety information, please see LUCENTIS full prescribing information.